Captrust Financial Advisors Trims Stock Holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors lowered its holdings in shares of Axsome Therapeutics, Inc. (NASDAQ:AXSM - Free Report) by 48.4% in the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 2,953 shares of the company's stock after selling 2,769 shares during the period. Captrust Financial Advisors' holdings in Axsome Therapeutics were worth $250,000 as of its most recent SEC filing.

Several other hedge funds have also made changes to their positions in AXSM. Assetmark Inc. acquired a new stake in Axsome Therapeutics in the fourth quarter valued at about $52,000. R Squared Ltd acquired a new stake in shares of Axsome Therapeutics during the fourth quarter valued at $64,000. Aquatic Capital Management LLC purchased a new stake in shares of Axsome Therapeutics during the fourth quarter worth about $76,000. KBC Group NV grew its stake in Axsome Therapeutics by 40.5% in the 4th quarter. KBC Group NV now owns 1,336 shares of the company's stock worth $113,000 after acquiring an additional 385 shares during the period. Finally, Xponance Inc. grew its position in shares of Axsome Therapeutics by 11.6% in the fourth quarter. Xponance Inc. now owns 2,659 shares of the company's stock valued at $225,000 after purchasing an additional 277 shares during the period. Institutional investors and hedge funds own 81.49% of the company's stock.

Axsome Therapeutics Stock Down 1.0%

Shares of NASDAQ AXSM traded down $1.09 on Tuesday, hitting $103.98. The company had a trading volume of 441,549 shares, compared to its average volume of 688,230. The company has a quick ratio of 2.04, a current ratio of 2.11 and a debt-to-equity ratio of 3.22. Axsome Therapeutics, Inc. has a 12-month low of $64.11 and a 12-month high of $139.13. The firm has a market capitalization of $5.12 billion, a P/E ratio of -17.36 and a beta of 0.46. The business has a 50 day moving average of $108.00 and a two-hundred day moving average of $105.98.

Analysts Set New Price Targets

AXSM has been the topic of several recent analyst reports. Bank of America increased their price objective on shares of Axsome Therapeutics from $143.00 to $167.00 and gave the stock a "buy" rating in a report on Tuesday, February 11th. Morgan Stanley increased their price target on shares of Axsome Therapeutics from $125.00 to $190.00 and gave the stock an "overweight" rating in a research note on Thursday, February 27th. Leerink Partners lifted their price target on shares of Axsome Therapeutics from $110.00 to $150.00 and gave the company an "outperform" rating in a report on Monday, February 10th. Jefferies Financial Group began coverage on Axsome Therapeutics in a report on Monday, April 7th. They set a "buy" rating and a $200.00 price objective for the company. Finally, HC Wainwright reaffirmed a "buy" rating and issued a $180.00 target price on shares of Axsome Therapeutics in a research report on Thursday, May 22nd. One analyst has rated the stock with a hold rating, fourteen have given a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock currently has a consensus rating of "Buy" and a consensus target price of $172.14.

Insider Activity

In related news, Director Mark Coleman sold 3,000 shares of the firm's stock in a transaction on Tuesday, May 20th. The shares were sold at an average price of $107.49, for a total transaction of $322,470.00. Following the completion of the sale, the director now directly owns 54,137 shares of the company's stock, valued at approximately $5,819,186.13. This trade represents a 5.25% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Insiders own 22.30% of the company's stock.

Axsome Therapeutics Company Profile

Axsome Therapeutics, Inc, a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States. The company's commercial product portfolio includes Auvelity (dextromethorphan-bupropion), a N-methyl-D-aspartate receptor antagonist with multimodal activity indicated for the treatment of major depressive disorder; and Sunosi (solriamfetol), a medication indicated to the treatment of excessive daytime sleepiness in patients with narcolepsy or obstructive sleep apnea.